Affiliation:
1. The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2. Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA
Abstract
AbstractBackgroundValganciclovir is approved for cytomegalovirus prophylaxis in pediatrics using the Pescovitz algorithm. There are reports of valganciclovir overdoses in children with low body surface area and overestimated creatinine clearance utilizing this algorithm. This study compared the incidence of neutropenia and cytomegalovirus infection between the Pescovitz and weight‐based dosing algorithms.MethodsA single‐center retrospective chart review from January 2010 to September 2018 was performed on pediatric heart, liver, and kidney transplant recipients, who received valganciclovir. Data were collected from the initiation of valganciclovir prophylaxis to 30 days after discontinuation. The primary objective was the incidence of neutropenia in patients receiving valganciclovir dosed by the Pescovitz versus weight‐based dosing algorithms.ResultsThis study included 187 pediatric transplant recipients who received valganciclovir dosed via the Pescovitz (62 recipients) or weight‐based dosing algorithms (125 recipients). The incidence of neutropenia was higher in the Pescovitz (69.4%) compared to the weight‐based dosing group (53.6%; p = .04) including moderate and severe neutropenia. Cytomegalovirus viremia was not significantly different between the two groups and occurred in 4.8% of the Pescovitz group compared to 2.4% of the weight‐based group (p = .4).ConclusionsThe incidence of neutropenia was greater in recipients receiving valganciclovir dosed via the Pescovitz algorithm compared to the weight‐based dosing. There were no significant differences in regard to cytomegalovirus viremia or disease between the two groups.
Reference9 articles.
1. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients
2. U.S. Food & Drug Administration.FDA Drug Safety Communication. U.S. Food & Drug Administration. FDA Drug Safety Communication.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐communication‐new‐dosing‐recommendations‐prevent‐potential‐valcyte‐valganciclovir. Accessed 2018 Aug 4.
3. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
4. Measurement and Estimation of Glomerular Filtration Rate in Children
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献